ReNeuron (RNUGF)

Executive Summary

ReNeuron is a UK-based cell and gene therapy company advancing its proprietary CustomEX™ exosome platform, designed for targeted delivery of therapeutics using engineered stem cells. Founded in 1997 and currently private, the company has achieved a valuation of approximately $63 million as of early 2026. ReNeuron's platform aims to address key limitations in drug delivery by enabling precise, customizable exosome-based therapies, potentially applicable across multiple disease areas including oncology, neurology, and rare genetic disorders. Despite limited public disclosures, the company appears to be in a pre-revenue stage, with no approved products or disclosed pipeline candidates. Recent efforts are likely focused on platform validation, preclinical studies, and securing partnerships to advance its technology toward clinical development. The CustomEX platform's ability to engineer exosomes for cell-specific targeting could position ReNeuron as a key player in the rapidly evolving exosome therapeutics space, though significant technical and regulatory hurdles remain.

Upcoming Catalysts (preview)

• Q3 2026Announcement of first strategic partnership for CustomEX platform60% success
• Q1 2027Presentation of preclinical proof-of-concept data for lead exosome candidate50% success
• Q2 2027Completion of Series B financing round to fund IND-enabling studies40% success